Antitumor Drugs
Antitumor Drugs
Antitumor Drugs
Cancer - TERMINOLOGY
- Spreading of a cancerous Metastasis growth by shedding cells that grow in other locations.
Neoplasm
In modern medicine, the term tumor is synonymous with a neoplasm that has formed a lump. Some neoplasms do not cause a lump.
Chemotherapy- the treatment of a disease by chemicals Cancer chemotherapy - the use of antineoplastic drugs or combination of these drugs to treat cancer
The cytoplasmic division of a cell at the end of mitosis or meiosis, bringing about the separation into two daughter cells
G0
Origins of Cancer
genetic material (DNA) of a cell become damaged or changed producing mutations affect normal cell growth and division cells do not die when they should new cells form when the body does not need them
extra cells
mass of tissue;
Cancer cells have four characteristics that distinguish them from normal cells
Divide without control / uncontrolled proliferation
Able to invade adjacent tissues Can spread to other parts of the body through the blood and lymph systems (metastasis)
10
11
Cell division
Cell differentiation
13
Cell Invasion
14
Cancer Metastasis
15
16
CANCER
Most cancers are named for the organ or type of cell in which they start
eg, cancer that begins in the colon is called colon cancer; basal cells of the skin basal cell carcinoma.
17
can often be removed, and in most cases, they do not recur Cells in benign tumors do not spread to other parts of the body.
Cells in these tumors can invade nearby tissues and spread to other parts of the body. The spread of cancer from one part of the body to another is called metastasis.
18
19
Carcinogenesis
is the process by which normal cells are transformed into cancer cells; generation of benign and malignant tumors caused by mutation of the genetic material (proto-oncogenes or tumor supressor genes) of normal cells, which disturbs the normal balance between proliferation and cell death*
20
21
Theories of carcinogenesis
1. Heredity (proto-oncogenes: & tumor suppressor genes) 2. Viral oncogenes 3. Chemicals & radiations 4. Failure of immune surveillance
HEREDITY
Cancer a disease of abnormal gene function. Genes pieces of DNA that contain the instructions on:
how to make the proteins that the body needs to function when to destroy damaged cells how to keep the cells in balance
24
25
Oncogenes are described by a two or threeletter code Usually derived from their first discovery
Ras oncogene a gene originally identified in rat sarcomas Abl first discovered in Ableson virus
Sometimes, the three-letter code is followed by a letter or number Allocation of a number indicates that the genes
Types of Cancer
Carcinoma (epithelial, or surface, tissue of organs) Sarcoma (bone, cartilage, connective tissue, fatty tissue) Myeloma (bone marrow plasma cells) Lymphoma (lymph system: lymphocytes & nodes) Leukemia (blood forming tissue)-flood of immature WBCs
There are a number of strategies in the administration of chemotherapeutic drugs used today.
Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms (to relieve or lessen without curing)
31
Treatment strategies:
The ultimate goal of treatment to achieve a cure (long term, diseasefree survival) A true cure requires elinimation of EVERY neoplastic cell
not achievable the goal control of the disease to stop the cancer from and spreading to extend
32
Treatment strategies:
Initial/early stage neoplastic cell burden can be reduced by surgery and/or by radiation, followed by chemotherapy, immunotherapy or combination of these treatment
In advanced stages of cancer possibility of controlling the cancer is far from reality
Thus, the goal of treatment is palliation (alleviation /lessening of symptoms and avoidance of life-threatening toxicity due to cancer)
33
Chemotherapy (Ctx) is indicated when neoplasms are disseminated/spread and are not responsive to surgery Ctx is also used as supplemental treatment i.e. to attack micrometastases following surgery & radiation treatment Adjuvant ctx Neoadjuvant ctx Ctx given prior to the surgical procedures in an attempt to shrink the cancer
A lessening of intensity or degree
American Cancer Society cancer remission is a "period of time when the cancer is responding to treatment or is under control. In a complete cancer remission, all the signs and symptoms of the disease disappear continue for several years considered cured Remission successsfully treated + safe
35
Treatment strategies: Tumor susceptibility and the growth cycle of tumor cells
Susceptible affected
easily
influenced
or
The fraction of tumor cells that are in the replicative cycle influences their susceptibility to cancer
Rapidly dividing cells more sensitive to drugs
eg. Cells of buccal mucosa, bone marrow, GI mucosa & hair
36
To cause a lethal cytotoxic event or apoptosis in the cancer cell arrest a tumors progression
The attack is generally directed toward DNA or against metabolic sites essential for cell replication
37
Eg
Methotrexate inhibit dihydrofolate reductase inhibition of purine (adenine / guanine) ring biosynthesis Cytarabine terminates DNA chain elongation and/or incorporated
38
39
Cell-cycle spesific (CCS) drugs = chemotherapeutic agents that are effective only against cycling /rapidly replicating cells
Egs. Antimetabolites, peptides antibiotics bleomycin
Cell-cycle nonspecific (CCNS) drugs = effective for both slowly proliferating cells (in solid tumors)
40
The growth rate of most solid tumors in vivo is initially rapid. But as the tumor size increases, the growth rate usually decreases.
Due to unavailability of nutrients and O2 caused by inadequate vascularization and lack of blood circulation
Reducing the tumor burden thru surgery or radiation often promotes the recruitment of the remaining cells into active
41
eg. A 3-log kill dose of an effective drug will reduce a cancer cell population of 1012 cells to 109. In this case, the dose reduces the numbers of cells by three orders of magnitude, or 3 logs
42
Combinations of drugs
Combination-drug chemotherapy is more successful than single drug treatment in most of the cancers for which chemotherapy is effective
43
Cytotoxic agents with qualitatively different toxicities, and with different molecular sites and mechanism of action are usually combined at full doses results in higher response rates due to additive cytotoxic effects and nonoverlapping host toxicities In contrast, agents with similar dose-limiting toxicities (myelosuppression, nephrotoxicity
44
45
Combination chemotherapy
Many cancer treatment protocols have been developed and each one is applicable to a particular neoplastic state
They are usually identified by an acronym /short form Eg. POMP a common regimen used for the tx of acute lymphocytic leukemia; consist of Prednisolone, Oncovin
46
Ewings sarcoma
Cyclosphosphamide + doxorubicin & vincristine
47
48
1) Resistance
Cancer drugs are toxins that produce a lethal threat to the cells therefore the cells have evolved complex defense mechanisms to protect themselves from chemical toxins, including chemotherapeutic agents Drug resistance is a major problem in cancer chemotherapy. In many cases, the resistance mechanisms involve changes in gene expression in neoplastic cells that can
49
Some neoplastic cells (eg. Melanoma) are naturally resistant to most anticancer drugs
Other tumor types may acquire resistance by mutating, particularly after prolonged administration of suboptimal drug doses
The development of drug resistance
50
Severe vomitting, stomatitis, bone marrow suppression, and alopecia occur to a lesser or greater extend during therapy with all antineoplastic agents
52
Adverse reactions confined to specific agents: Cardiotoxicity doxorubicin pulmonary fibrosis bleomycin
Immediate effects
Occur soon after cancer chemotherapy drug administration Eg. Nausea, vomiting, mouth ulcers, blistering and necrosis of skin
Delayed effects
Observed sometime after drug therapy starts Eg. Suppression of bone marrow cells, myelosuppression (decreased production of blood cells), alopecia
54
Because most antineoplastic agents are mutagens, neoplasms may arise 10 or more years after the original cancer was cured.
(mutagens = agent that changes the genetic material, usually DNA)
Treatment-induced neoplasms are especially a problem after therapy with alkylating agents (???)
56
ANTICANCER DRUGS
57
ANTICANCE R DRUGS
ANTIMETABOLITES MICROTUBULE INHIBITORS
ALKYLATING AGENTS
MONOCLONAL ANTIBODIES
ANTITUMOR ANTIBIOTICS
58
(1) ANTIMETABOLITES
Antimetabolites are structurally related to normal compounds that exist within the cell They generally interfere with the availability of normal purine or pyrimidine nucleotide precursors, either by inhibiting their synthesis or by competing with them in DNA or RNA synthesis Their maximal cytotoxic effects are in Sphase therefore they are cell-cycle
59
Antimetabolites:
Methotrexate , 6-mercaptopurine, 6thioguanine fludarabine, cladribine, 5-fluorouracil, capecitabine floxuridine, cytarabine, gemcitabine
60
61
Cytarabine (cytosine arabinoside- AraC) is activated by kinases to AraCTP, an inhibitor of DNA polymerases
*of all the antimetabolites, cytarabine is the most specific for the S-phase of the tumor cell cycle Resistance to cytarabine can occur through decreased uptake of AraC or a decreased conversion to AraCTP
62
Purine antimetabolites (and fluorouracil) are effective after oral administration The pyrimidine antimetabolites are usually given intravenously
Antimetabolites: pharmacokinetics
Antimetabolites: toxicity
Common adverse effects include bone marrow suppression and toxic effects on the skin and GI mucosa (mucositis). Purine antimetabolites may cause dosedependent hepatic dysfucntion The toxic effects of methotrexate on normal cells may be reduced by administration of folinic acid (leucovorin) this strategy is called leucovorin rescue
64
*intercalation = Insertion of a flat aromatic molecule between adjacent base pairs of the DNA double helix.
2)
3)
inhibit
65
ANTITUMOR ANTIBIOTICS
Dactinomycin Doxorubicin & daunorubicin Bleomycin
66
ANTITUMOR ANTIBIOTICS: MECHANISM OF ACTIONS Dactinomycin this is a CCNS drug that binds to double-stranded DNA and inhibits DNA-dependent RNA synthesis
Anthracyclins: This is a CCNS drugs - can intercalate between base Doxorubicin & pairs to block DNA and RNA synthesis, cause membrane daunorubicin disruption and generation of free radicals that lead to cardiotoxicity
Bleomycin
This agent is a mixture of glycopeptides that generate free radicals which bind to DNA and cause DNA strand breaks and inhibit DNA synthesis. These peptides are CCS drugs active in the G2 phase of the tumor cell cycle
67
Important features include: 1) the metabolism of anthracyclins by liver enzymes to form both active and inactive metabolites that are excreted in the bile
2)
the inactivation of bleomycins by tissue aminopeptidases- but some renal clearance of intact drug also occurs
The short half-life of dactinomycin, with intact drug excreted in the bile
68
3)
Doxorubicin is a component of the tx regimens used in Hodgkins disease, myelomas and sarcomas Bleomycin is a component of the tx regimen for testicular carcinoma Dactinomycin is used in melanomas and Wilms tumor
69
Before their use in chemotherapy, alkylating agents were better known for their use as sulfur mustard, ("mustard gas") and related chemical weapons in World War I.
1943- Goodman & Gilman were prompted to study nitrogen mustards as a potential treatment for cancer following an incident in Bari, Italy, where survivors exposed to mustard gas became leukopenic*.
An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group (CnH2n+1) to DNA. The alkyl group is attached to the guanine base of DNA of cancer cells Exert their cytotoxic effects by forming reactive molecular species that alkylate nucleophilic groups on DNA bases, particularly the N7 postion of guanine in DNA double-helix strands. This leads to cross-linking of bases, abnormal base-pairing, makes the strands unable to uncoil and separate and/or DNA strand breakage.. As this is necessary in DNA replication, the cells can no longer divide.
72
Alkylating agents do not discriminate between cycling and resting cells, but most toxic for rapidly dividing cells They are used in combination with other agents to treat a wide variety of lymphatic and solid cancers. In addition to being cytotoxic, all are mutagenic and carcinogenic and can lead to second malignancies, such as acute leukemia
73
ALKYLATING AGENTS
Mechlorethamine Cyclophosphamide & ifosfamide Nitrosoureas Dacarbazine Temozolomide Others: melphalan, chlorambucil, busulfan
74
Tumor cell resistance to alkylating agents occurs through increased DNA repair, decreased drug permeability, or the production of trapping agents as thiols (eg. Glutathione).
Some tumor cells increase their production of thiol trapping agents, which interact with the reactive molecular species formed by the anticancer drugs inactive
75
These agents are important in combination regimens for the therapy of lymphomas, leukemias and myelomas.
Eg. Mechlorethamine is a component of a multidrug regimen for Hodgkins disease
Common toxic effects include: Bone marrow suppression leukopenia, thrombocytopenia GI irritation Changes in gonadal function The use of cyclosphosphamide is associated with a high incidence of alopecia & hemorrhagic cystitis Busulfan adrenal insufficiency, pulmonary fibrosis and increased skin
77
The mitotic spindle is part of a larger, intracellular skeleton (cytoskeleton) that is essential for the movements of structures occurring in the cytoplasm of all eukaryotic cells it consists of chromatin + microtubules (composed of protein tubulin)
78
MICROTUBULE INHIBITORS
The mitotic spindle is essential for the equal partitioning of DNA into two daughter cells that are formed when a cell divides Several plant-derived substances used as anticancer drugs disrupt this process by affecting the equilibrium between the polymerized and depolymerized forms of the
79
MICROTUBULE INHIBITORS
80
VINCRISTINE (VX) & VINBLASTINE (VBL) Mechanism of action VX and VBL are both cell-cycle specific and phase specific, because they block mitosis in metaphase (M phase). Their binding to the microtubular protein, TUBULIN blocks the ability of tubulin to polymerize to form microtubules. Instead paracrystalline aggregates consisting of tubulin dimers and the the alkaloid drug are formed. The resulting dysfunctional spindle apparatus, frozen in metaphase, prevents chromosomal segregation and cancer cell proliferation.
Resistance
Resistant tumor cells have been shown to have enhanced efflux of VX and VBL via p-glycoprotein in the cell membrane. Alterations in tubulin structure of the tumor cells may also affect binding of the vinca alkaloids
81
Pharmacokinetic IV injection of these agents leads to rapid cytotoxic effects and cell destruction. This is turn can cause hyperuricemia (high uric acid in blood) due to the oxidation of purines that are released from fragmenting DNA molecules. The hyperuricemia is ameliorated by administration of the xanthine oxidase-inhibitor Allopurinol.
The vinca alkaloids are concentrated and metabolized in the liver by the cytochrome P450 pathway. They are excreted into bile and feces. Doses must be modified in patients with impaired hepatic function or biliary obstruction
Adverse effects
Phlebitis, alopecia
PACLITAXEL & DOCETAXEL Mechanism of action Both drugs are active in the G2/M phase of the cell cycle. They bind reversibly to the B-tubulin subunit, but unlike the vinca alkaloids, they promote polymerization and stabilization of the polymer. Thus, they shift the depolymerization polymerization process to accumulation of microtubules. The overly stable microtubules formed are nonfunctional, and thus, chromosome desegregation does not occur. This results in cell death.
Resistance
Like the vinca alkaloids, resistance has been associated with the presence of amplified Pglycoprotein or a mutation in the tubulin structure
83
PACLITAXEL & DOCETAXEL Pharmacokinetic Both drugs have a large volume of distribution but neither enter the CNS. Hepatic metabolism by the cytochrome P450 system and biliary excretion are responsible for their elimination into the stool/feces.
Adverse effects
The dose-limiting toxicity of both drugs is neutropenia (low neutrophils). Patients with fewer than 15000 neutrophils/mm3 should not be given these agents. Treatment with granulocyte-colony-stimulating factor (Filgrastim) can help to reverse neutropenia.
84
Hormone-dependent in which removal of a hormonal stimulus causes tumor regression removal of hormonal stimuli from hormonedependent tumors can be accomplished by surgery (orchiectomy for patients with advanced prostate cancer) or by drugs (eg. Antiestrogen tamoxifen)
85
For a steroid hormone to influence a cell, that cell must have intracellular (cytosolic) receptors that are specific for that hormone
86
Prednisone Tamoxifen Aromatase inhibitors Progestins Leuprolide & goserelin Estrogens Flutamide, nilutamide & bicalutamide
87
PREDNISONE
Mechanis m of action
Prednisone is a potent, synthetic , antiinflammatory corticosteroid with less mineralocorticoid activity than cortisol.
Prednisone itself is inactive and reduced to prednisolone hydroxysteroid dehydrogenase. then binds to a receptor that production of specific proteins. must first be by 11-BThis steroid triggers the
Resistanc resistance is associated with an absence of e the receptor protein or a mutation that lowers receptor affinity for the hormone.
88
PREDNISONE Pharmacokinetic Prednisone is readily absorbed orally. It is bound to plasma albumin and transcortin. It undergoes 11-Bhydroxylation to prednisolone in the liver. Prednisolone is the active drug and it is glucuronidated and excreted into the urine along with the parent compound.
Adverse effects
89
Monoclonal antibodies (Mab) have become an active area of drug development for anticancer therapy and other nonneoplastic diseases, because they are directed at specific targets and often have fewer adverse effects MAb are created from B lymphocytes (from immunized mice/hamsters) fused with immortal B lymphocytes tumor cells the resulting hybrid can be
90
Recombinant technology has led to the creation of humanized abs that overcome the immunologic problems following administration of mouse (murine) abs.
Others: (1) gemtuzumab ozogamicin a MAb conjugated with a plant toxin that binds to
91
(7) OTHER CHEMOTHERAPEUTIC AGENTS Platinum coordination complexes Irinotecan & topotecan Etoposide Imatinib Gefitinib Procarbazine L-asparagine Interferons
92
THE END
93